Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial

Dextromethorphan (DM)/quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based upon efficacy and safety trials in patients with PBA secondary to amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PBA treatment in patients with stroke, dementia or traumatic brain injury.
Source: PM and R - Category: Rehabilitation Authors: Source Type: research

Related Links:

Publication date: Available online 16 October 2018Source: Journal of Neuroscience MethodsAuthor(s): Wilson BarnabasAbstractBrain specific drug delivery is one of the most interesting and challenging areas of research. The blood-brain barrier separates the brain from blood and acts as a barrier to protect the brain from microorganisms, neurotoxins and chemical substances. But, the same mechanism poses an obstacle for the entry of many drugs into the brain. Worldwide, approximately 1.5 billion people are suffering from CNS disorders, such as Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, amyotrophi...
Source: Journal of Neuroscience Methods - Category: Neuroscience Source Type: research
Publication date: Available online 30 June 2018Source: PM&RAuthor(s): Richard D. Zorowitz, David N. Alexander, Andrea E. Formella, Fred Ledon, Charles Davis, Joao SiffertAbstractBackgroundDextromethorphan (DM)/quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based upon efficacy and safety trials in patients with PBA secondary to amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PBA treatment in patients with stroke, dementia or traumatic brain injury.ObjectiveTo report results from the stroke cohort of PRISM II, including the Stroke Impact Scale (SIS).DesignOpen-lab...
Source: PMandR - Category: Rehabilitation Source Type: research
Authors: Tae WS, Ham BJ, Pyun SB, Kang SH, Kim BJ Abstract Diffusion-tensor imaging (DTI) is a noninvasive medical imaging tool used to investigate the structure of white matter. The signal contrast in DTI is generated by differences in the Brownian motion of the water molecules in brain tissue. Postprocessed DTI scalars can be used to evaluate changes in the brain tissue caused by disease, disease progression, and treatment responses, which has led to an enormous amount of interest in DTI in clinical research. This review article provides insights into DTI scalars and the biological background of DTI as a relative...
Source: Journal of Clinical Neurology - Category: Neurology Tags: J Clin Neurol Source Type: research
Conclusions DM/Q was well tolerated and significantly reduced PBA episodes in study participants with TBI. Changes in CNS-LS and PBA episode count were similar to changes with DM/Q in phase 3 trials.
Source: PMandR - Category: Rehabilitation Source Type: research
In conclusion, the present study demonstrated that TIGIT is a prominent negative immune regulator involved in immunosenescence. This novel finding is highly significant, as targeting TIGIT might be an effective strategy to improve the immune response and decrease age-related comorbidities. Delivery of Extracellular Vesicles as a Potential Basis for Therapies https://www.fightaging.org/archives/2018/01/delivery-of-extracellular-vesicles-as-a-potential-basis-for-therapies/ Here I'll point out a readable open access review paper on the potential use of extracellular vesicles as a basis for therapy: harveste...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Conclusion: This novel technology discriminates and quantifies subtle differences in behavior and neurological impairments in subjects afflicted with neurological injury/disease. KINARM assessments can be incorporated into multi-center trials (e.g., monitoring stroke motor recovery: NCT02928393). Further studies will determine if KINARM Labs can demonstrate a clinical effect with fewer subjects over a shorter trial period. Disclosures/funding: Dr. Stephen Scott is the inventor of KINARM and CSO of BKIN Technologies.   Multiplexed mass spectrometry assay identifies neurodegeneration biomarkers in CSF Presenter: Chelsky...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Assessment Tools biomarkers Cognition Current Issue Drug Development General Genetics Medical Issues Neurology Patient Assessment Psychopharmacology Scales Special Issues Supplements Trial Methodology clinical trials CNS Su Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Royal Philips (NYSE:PHG) said today it launched its IntelliSpace Portal 9.0, the most recent iteration of its radiological visual analysis and quantification platform. The new version of the platform utilizes machine learning to aid operating radiologists in detecting, diagnosing and following-up on treatment for diseases and traumas, such as brain juries and neurological disorders including dementia, stroke, amyotrophic lateral sclerosis and multiple sclerosis. “As the rates of dementia and neurodegeneration rise, neuroradiologists need advanced tools to help referring physicians treat these challenging cases. ...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Imaging Software / IT Royal Philips Source Type: news
Worldwide,  nearly44 million  people now have Alzheimer's disease (AD) or related dementia, making these conditions the  top cause of disabilities in later life. The biopharma industry has invested billions of dollars into research to treat and prevent AD1, yet this work has faced many obstacles, including difficulty identifying biomarkers, tracking the disease ’s progress in the brain, and recruiting patients to trials while they are still asymptomatic. But in recent years, we’ve begun to see breakthroughs that is driving our research in new directions. Many of these accomplishments were hi...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news
Phase 3 trials supporting dextromethorphan/quinidine (DM/Q) use as a treatment for pseudobulbar affect (PBA) were conducted in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). The ...
Source: BMC Neurology - Category: Neurology Authors: Source Type: research
More News: ALS | Brain | Dementia | Multiple Sclerosis | Neurology | Stroke